SUNNYVALE, Calif.--(BUSINESS WIRE)--Labcyte, whose Echo® liquid handling platforms move liquids with sound, today announced the grant of its first patent in China. Patent CN 101035681B describes how acoustic energy is used to assess the characteristics of any fluid in real time to optimize its transfer. The Labcyte acoustic droplet ejection technology offers touchless transfer of a wide variety of liquids, with major benefits in life science applications including drug discovery, genomics, proteomics and diagnostics.

“The life sciences industry in China is the world’s highest growth market and the pharmaceutical and biotech markets are expected to be the 3rd largest market, after the USA and EU, in the world by 2013 at $73 billion,” said Sanger Chang, General Manager of Tekon Biotech, the Labcyte distributor in China. “Labcyte products have already been successfully adopted by some of the largest pharmaceutical and CRO companies in China as well as by all ten of the top ten pharmaceutical companies globally. As discovery platforms are standardized and adopted globally we see significant opportunity for the Labcyte products in China.”

“This new feature—already incorporated in our products—allows customers to transfer liquids for a wide range of applications including siRNA screening, qPCR, genotyping and total assay assembly for drug discovery,” said Rich Ellson, Labcyte CTO. “Customers have chosen Echo liquid handlers because they provide better precision and accuracy, reduce operating costs and eliminate cross-contamination. The technology described in the patent allows users to transfer many different fluids with factory-installed calibrations that require no user customization. The built-in intelligence of the Echo platform automatically optimizes fluid transfer well by well.”

About Labcyte

Labcyte, a global biotechnology tools company, is revolutionizing liquid handling. Our Echo liquid handling platforms use sound for the precise transfer of liquids. The environmentally friendly Echo systems generate better results with lower costs when compared to traditional liquid handling systems that have high running costs, are prone to transfer errors, have risk of sample contamination and waste large amounts of plastic lab consumables. Labcyte equipment is used by all 10 of the top 10 pharmaceutical companies, as well as by small to mid-size pharmaceutical companies, biotechnology firms, contract research organizations and academic institutions. Our customers work across a wide spectrum of biology including drug discovery; genomics; proteomics; diagnostics; imaging mass spectrometry and the transfer of live cells. Labcyte, headquartered in Sunnyvale, California, has global sales and support. Labcyte has 41 U.S., 8 European, 3 Japanese and 1 Chinese patents with additional U.S. and international filings. For more information, visit www.labcyte.com.

About Tekon Biotech

Tekon Biotech, founded in 1988, sells and supports a broad range of technologies to the China life sciences market. Tekon’s customers include all the major pharmaceutical and biotech companies plus the top 50 universities. Tekon is headquartered in Shanghai with offices in Hong Kong and Taipei. Tekon Biotech takes pride in providing the best service and technical support. For more information, visit www.tekon.net.